Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX:6704)

Taiwan · Delayed Price · Currency is TWD

19.10

-0.60 (-3.05%)

Aug 4, 2026, 1:43 PM CST

-17.32% (1Y)

Market Cap	1.89B -14.7%
Revenue (ttm)	187.02M +10.0%
Net Income	-80.52M
EPS	-0.84
Shares Out	95.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,587
Open	19.70
Previous Close	19.70
Day's Range	18.80 - 19.70
52-Week Range	18.20 - 33.65
Beta	0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About TPEX:6704

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the tr... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 6704

Full Company Profile

Financial Performance

In 2025, TPEX:6704's revenue was 187.02 million, an increase of 10.00% compared to the previous year's 170.03 million. Losses were -80.52 million, -3.36% less than in 2024.

Financial Statements